ARVN — Arvinas, Inc.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for ARVN in the TickerWise workspace.

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ Global Select
• Employees: 430
• Website: https://www.arvinas.com

Latest SEC filings for ARVN

• 2026-09-28S-8
• 2026-08-14SCHEDULE 13G/A
• 2026-06-258-K
• 2026-06-228-K
• 2026-06-168-K
• 2026-06-028-K
• 2026-05-128-K
• 2026-05-128-K
• 2026-05-1110-Q
• 2026-05-018-K

Latest ARVN news

• 2026-10-13Reasons Why Investors Should Consider Betting on Arvinas Stock Read article
• 2026-10-07Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease Read article
• 2026-10-01Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders® Read article
• 2026-09-29Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Read article
• 2026-09-28Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate Read article

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.